Peptidase inhibitors significantly prolonged dynorphin A and B's pain-relieving effects when injected into the spinal cord, confirming rapid enzymatic breakdown limits their natural analgesic duration.
Extended pain relief durationPeptidase inhibitors significantly prolonged dynorphin-mediated analgesia in the mouse formalin pain test
What the researchers found
Peptidase inhibitors significantly prolonged the antinociceptive effect of intrathecally administered dynorphin A (0.5-2 nmol) and dynorphin B (2-8 nmol) in the formalin test.
Why it matters
If dynorphin's rapid breakdown can be slowed, its natural pain-relieving properties could be therapeutically enhanced without using synthetic opioids.
How the study worked
Mouse formalin test: dynorphin A or B was injected intrathecally 5 minutes before 0.5% formalin injection into a hindpaw. Pain response was measured with and without co-administered peptidase inhibitors.
What this study cannot tell us
Mouse study with spinal injection — not a practical administration route. The formalin test models inflammatory pain specifically. Peptidase inhibitor side effects not assessed.
How to read the evidence
Moderate animal evidence with clear dose-response data and a well-established pain model.
When this study was published
Published in 1996, contributing to research on enhancing endogenous opioid peptide activity as an alternative to synthetic opioids.
The bigger picture
Enhancing endogenous opioid peptide activity by protecting them from breakdown represents an alternative approach to pain management that could avoid the side effects and addiction risks of synthetic opioids.
Questions still open
- Could systemically administered peptidase inhibitors enhance natural pain relief in humans?
- Which specific peptidases are most important for dynorphin degradation in the spinal cord?
Common questions
What are peptidase inhibitors?
Why does dynorphin need protection?
Read the original research
Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test.
European journal of pharmacology, 314(1-2), 61-7
Citation
Tan-No, K; Taira, A; Sakurada, T; Inoue, M; Sakurada, S; Tadano, T; Sato, T; Sakurada, C; Nylander, I; Silberring, J; Terenius, L; Kisara, K. (1996). Inhibition of dynorphin-converting enzymes prolongs the antinociceptive effect of intrathecally administered dynorphin in the mouse formalin test.. European journal of pharmacology, 314(1-2), 61-7.